source
- The capacity crunch in biopharma is a location problemCell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change the math on scaling.BioPharma Dive · 2mo ago↗ source
- Lilly to invest extra $4.5B across Indiana manufacturingThe Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss drugs.BioPharma Dive · 2mo ago↗ source
- FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extendedPierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.BioPharma Dive